ProtoKinetix, Inc. 8-K

What Happened
ProtoKinetix, Inc. (PKTX) filed an 8‑K reporting board changes, the formation of a new subsidiary for ocular drug development, late‑filing notices for its 2025 10‑K and 2026 Q1 10‑Q, and repricing of stock options and warrants. On March 31, 2026 Edward McDonough resigned from the board (not due to any disagreement). On June 17, 2026 Michael Jones and Jason Lamp were appointed directors, and Dr. Keith R. Brunt (age 47) was appointed director and president. On February 11, 2026 the company formed SightPath Biotech LLC to develop PKX‑001 for dry‑eye and other ophthalmic indications; the underlying patents remain owned by ProtoKinetix. The company filed Form 12b‑25 notices on March 31 and May 15, 2026 for late 2025 10‑K and 2026 Q1 10‑Q filings and says it is working to file those reports.

Key Details

• Board changes: Edward McDonough resigned effective March 31, 2026; Michael Jones and Jason Lamp added as directors on June 17, 2026; Dr. Keith R. Brunt named director and president on June 17, 2026. Dr. Brunt has served as the company’s Medical Science Advisor since 2019.
• Subsidiary & IP valuation: SightPath Biotech LLC formed Feb 11, 2026 to develop PKX‑001; two independent valuations (IQVIA 2021 and Benoit & Cote 2025) place the present value of the related patents and development work at approximately $253 million.
• Option/warrant repricing: On June 17, 2026 the board approved repricing 61,190,000 stock options from $0.028 to $0.01 and extending expiration from Dec 6, 2028 to Dec 6, 2030. Also repriced warrants to acquire 6,000,000 shares from $0.028 to $0.01 and extended expiration from Dec 12, 2028 to Dec 12, 2030.
• Regulatory filings: Company filed Form 12b‑25 notices for late filing of the 2025 Form 10‑K (filed Mar 31, 2026) and the 2026 Q1 Form 10‑Q (filed May 15, 2026) and states it is preparing those reports.

Why It Matters

• Leadership: Appointment of Dr. Brunt as president and director signals an operational emphasis on scientific and clinical development, particularly given his background and prior advisory role.
• Asset focus: Creation of SightPath centralizes development of the company’s ophthalmic program (PKX‑001) while the company retains the patents; the independent ~$253M valuation highlights the perceived value of those assets.
• Shareholder impact: The large‑scale repricing and term extensions for options and warrants change the exercise economics for holders and affect potential future dilution and incentive structures.
• Compliance: The Form 12b‑25 filings show the company has not yet filed its 2025 10‑K and 2026 Q1 10‑Q and is working to complete them, which is important for investors tracking financial disclosure and SEC compliance.